JPRN-jRCT2080225044已完成2 期
A Phase 2a Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects With Diabetic Kidney Disease
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Adult men or women 18 years of age or more.
- •2. Diabetic kidney disease DKD defined as:
- •a. diagnosis of T2DM
- •b. eGFR 25-75 mL/min/1.73 m2
- •c. UACR 100-3000 mg albumin/g creatinine
- •3. BP 150/100 mmHg or less
- •4. Stable dose of ACEi or ARB Key Exclusion Criteria
排除标准
- •1. Serum potassium > 5.5 mmol/L
- •2. Significant hepatic disease
- •3. Hemoglobin A1c > 10.5 %
- •4. B-type natriuretic peptide level > 200 pg/mL
- •5. History of clinically significant heart disease
- •6. Anticipated dialysis or renal transplantation within 1 year
- •7. History of underlying condition that predisposes the subject to infections
- •8. Significant infection (viral, bacterial, or fungal)
- •9. Amputation due to peripheral artery disease
- •10. Subjects with a positive diagnostic nucleic acid test for SARS-CoV-2
- •11. Pregnancy, breastfeeding or intention to become pregnant during the course of the study,
- •12. Any other medical condition or clinically relevant abnormal findings in physical examination, laboratory results, or electrocardiogram (ECG) during screening that, in the opinion of the investigator, may compromise the safety of the subject in the study, reduce the subject's ability to participate in the study, or interfere with evaluation of the investigational product
研究者
相似试验
进行中（未招募）
不适用
未命名试验Influenza A (H1N1) infectionMedDRA version: 18.0Level: LLTClassification code 10063211Term: Influenza A virus IgGSystem Organ Class: 100000004848EUCTR2015-000574-35-BEVisterra, Inc.
已完成
2 期
A Study of JNJ-64304500 as Add-on Therapy in Participants with Active Crohn's DiseaseCrohn DiseaseJPRN-jRCT2031200406umaguchi Hirotaka70
进行中（未招募）
1 期
aProphylactic H3N2(A/Brisbane/10/2007) monovalent influenza vaccine, Bris10 M2SR, for protection against influenza disease caused by seasonal influenza A viruses.MedDRA version: 20.0 Level: HLT Classification code 10022005 Term: Influenza viral infections System Organ Class: 100000004862EUCTR2017-004971-30-BEFluGen, Inc120
进行中（未招募）
1 期
A phase 2a study of CR9114 in healthy adult participantsInfluenza virusCTIS2023-505020-57-00eyden Laboratories B.V.140
进行中（未招募）
1 期
A clinical study to evaluate the safety and effectiveness of JNJ-64304500 as an add-on therapy to standard of care biologic therapy with anti-tumor necrosis factor alpha or anti-interleukin 12/23 in responder not remitter participants with active Crohn's DiseaseEUCTR2020-002701-26-ITJANSSEN CILAG INTERNATIONAL NV70